Skip navigationU.S. Food and Drug Administration Center for Drug Evaluation and Research

CDER - Center for Drug Evaluation and Research Logo

Office of Generic Drugs

Reference Listed Drug Labeling and Efficacy Supplements Approved in June 2002

Click on appropriate hyperlink below to view available source document in PDF format.

Approval Date

Product Name

 

 

Active Ingredient(s)

Dosage Form

NDA No

Supp No

   TRIZIVIR   letter label

abacavir sulfate, lamivudine, zidovudine

tablets

21-205 SLR 004
 Jun 4 CAFERGOT letter label

ergotamine tartrate and caffeine

suppositories

09-000 SLR 022
   M.V.I.-12 letter  

multi-vitamins for infusion

injection

08-809 SLR 046
    PEPCID injection letter label

famotidine

injection

20-249 SE8 011
    PEPCID oral susp letter label

famotidine

oral suspension

19-527 SE8 024
 Jun 6 PEPCID injection letter label

famotidine

injection

19-510 SE8 028
    PEPCID tablets letter label

famotidine

tablets

19-462 SE8 030
    BIAXIN letter   

clarithomycin

tablets

50-662 SLR 031
Jun 7 LOTRONEX letter label

alosetron HCl

tablets

21-107 SE8 005
    CELEBREX letter label

celecoxib

capsules

20-998 SE8 009
   ACTIQ letter  

fentanyl citrate

oral transmucosal

20-747 SLR 011
      RETIN-A letter label

treinoin

cream

19-049 SLR 011
Jun 10 RETIN-A letter label

treinoin

liquid

16-921 SLR 021
     RETIN-A letter label

treinoin

cream

17-522 SLR 022
     RETIN-A letter label

treinoin

cream

17-579 SLR 023
    RETIN-A letter label

treinoin

gel

17-955 SLR 023
Jun 11 APHTHASOL letter label

amlexanox

oral paste

20-511 SLR 002
   SARAFEM letter label

fluoxetine HCl

capsules

18-936 SE2 067
Jun 12 AVELOX letter label

moxofloxacin

tablets

21-085 SLR 007
   NEORAL letter label

cyclosporine

capsules

50-715 SLR 014
   NEORAL letter label

cyclosporine

oral solution

50-716 SLR 018
   NASCOBAL letter      

cyanocobalamin

nasal gel

19-722 SLR 004
Jun 14 ESTROSTEP FE letter   

norethindrone acetate/ethinyl estradiol

tablets

20-130 SLR 009
    CEREZYME letter label

imiglucerase

injection

20-367 SLR 053
   COLAZAL letter   

balsalazide disodium

capsules

20-610 SLR 001
   MONODOX letter   

doxycycline monohydrate

capsules

50-641 SLR 010
  VIBRAMYCIN letter   

doxycycline hyclate

capsules

50-007 SLR 014
Jun 18 VIBRAMYCIN letter   

doxycycline hyclate

injection

50-442 SLR 015
  DORYX letter   

doxycycline hyclate

capsules

50-582 SLR 016
  VIBRA-TABS letter   

doxycycline hyclate

tablets

50-533 SLR 030
  VIBRAMYCIN letter   

doxycycline calcium

syrup

50-480 SLR 035
    VIBRAMYCIN letter   

doxycycline monohydrate

oral suspension

50-006 SLR 074
   LOTREL letter   

amlodipine and benazepril HCl

capsules

20-364 SE8 016
   ISOVUE-370 letter   

iopamidol

injection

20-327 SLR 002
   ANGIOMAX letter   

bivalirudin

injection

20-873 SLR 004
Jun 20 WELLBUTRIN SR letter   

bupropion

tablets

20-358 SLR 018
  WELLBUTRIN letter   

bupropion

extended-release tablets

18-644 SLR 023
  OPHTHETIC letter label

proparacaine HCl

ophthalmic sol

12-583 SLR 028
  SERZONE letter   

nefazodone HCl

tablets

20-152 SLR 033
   SKELAXIN letter   

metaxalone

tablets

13-217 SLR 044
  ACCUTANE letter label

isotretinoin

capsules

18-662 SLR 051
    CRIXIVAN letter label

indinavir

capsules

20-685 SLR 056
Jun 21 CENESTIN letter label

synthetic conjugated estrogens

tablets

20-992 SE1 016
Jun 24 EPIVIR letter label

lamivudine

tablets

20-564 SE2 015
   EPIVIR letter label

lamivudine

oral solution

20-596 SE2 016
Jun 26 NEUTREXIN letter label

trimexate glucoronate

injection

20-326 SLR 013
Jun 28 PARAFON FORTE letter   

chlorzoxazone

tablets

11-529 SLR 048

totop.gif (1525 bytes) Back to Top

Back Labeling Review Branch Page

FDA/Center for Drug Evaluation and Research
Last Updated: January 18, 2006
Originator: OTCOM/DLIS
HTML by JFG